This page is translated by Google and can contain errors. Go back to English.
  1. Home
  2. News

News

The Anticancer Fund’s recommendations to Horizon Europe

Launch of a Call for Research Proposal

Low-dose azacytidine, pioglitazone and retinoic acid in ≥ 60 years patients with acute myeloid leukaemia refractory to chemotherapy (AML-ViVA)

Presented on the 61st ASH Annual Meeting & Exposition

Intraoperative ketorolac in High-Risk Breast Cancer Patients. A Prospective, Randomized, Placebo-Controlled Clinical Trial.

Patrice Forget, Gauthier Bouche, Francois P. Duhoux, Pierre G. Coulie,Jan Decloedt, Alain Dekleermaker, Jean-Edouard Guillaume, Marc Ledent, Jean- Pascal Machiels, Véronique Mustin, Walter Swinnen, Aline van Maanen, Lionel Vander Essen, Jean-Christophe Verougstraete, Marc De Kock, Martine Berliere (2019) - Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS ONE 14(12): e0225748. https://doi.org/10.1371/journal.pone.0225748

More than 300 existing drugs have anticancer effects

Journal retractions in oncology: a bibliometric study

Pan Pantziarka, Lydie Meheus - Journal retractions in oncology: a bibliometric study. Future Medicine, 15 (31), DOI: 10.2217/fon-2019-0233